A new asset in contraception: E4 14.2 mg + DRSP 3 mg

Oral contraception is a great asset in family planning that leads to female empowerment. In this podcast three leading experts from the field of gynecology and hemostasis Kristina Gemzell Danielsson, Diana Mansour and Jonathan Douxfils discuss the brief history and development of combined oral contraceptives and talk about access to contraception during the COVID-19 pandemic. They will also have a discussion about the present situation of VTE risk and combined hormonal contraception and will present data on effect on hemostasis parameters of the estetrol 14.2 mg and drospirenone 3 mg combination. (14.2 mg estetrol as 15 mg estetrol monohydrate)

Disclaimer: The publication of this podcast was funded by Gedeon Richter. The discussion represents the opinion of the speakers and was not influenced by Gedeon Richter. The information contained in this podcast is solely for healthcare professionals and is not for an audience without the relevant education. It is not intended as, and shall not be understood or construed as, medical or health advice.